Preference-adaptive randomization in comparative effectiveness studies

Benjamin French, Dylan S Small, Julie Novak, Kathryn A Saulsgiver, Michael O Harhay, David A Asch, Kevin G Volpp, Scott D Halpern, Benjamin French, Dylan S Small, Julie Novak, Kathryn A Saulsgiver, Michael O Harhay, David A Asch, Kevin G Volpp, Scott D Halpern

Abstract

Background: Determination of comparative effectiveness in a randomized controlled trial requires consideration of an intervention's comparative uptake (or acceptance) among randomized participants and the intervention's comparative efficacy among participants who use their assigned intervention. If acceptance differs across interventions, then simple randomization of participants can result in post-randomization losses that introduce bias and limit statistical power.

Methods: We develop a novel preference-adaptive randomization procedure in which the allocation probabilities are updated based on the inverse of the relative acceptance rates among randomized participants in each arm. In simulation studies, we determine the optimal frequency with which to update the allocation probabilities based on the number of participants randomized. We illustrate the development and application of preference-adaptive randomization using a randomized controlled trial comparing the effectiveness of different financial incentive structures on prolonged smoking cessation.

Results: Simulation studies indicated that preference-adaptive randomization performed best with frequent updating, accommodated differences in acceptance across arms, and performed well even if the initial values for the allocation probabilities were not equal to their true values. Updating the allocation probabilities after randomizing each participant minimized imbalances in the number of accepting participants across arms over time. In the smoking cessation trial, unexpectedly large differences in acceptance among arms required us to limit the allocation of participants to less acceptable interventions. Nonetheless, the procedure achieved equal numbers of accepting participants in the more acceptable arms, and balanced the characteristics of participants across assigned interventions.

Conclusions: Preference-adaptive randomization, coupled with analysis methods based on instrumental variables, can enhance the validity and generalizability of comparative effectiveness studies. In particular, preference-adaptive randomization augments statistical power by maintaining balanced sample sizes in efficacy analyses, while retaining the ability of randomization to balance covariates across arms in effectiveness analyses.

Trial registration: ClinicalTrials.gov, NCT01526265; 31 January 2012.

Figures

Figure 1
Figure 1
Probability of being allocated to each incentive structure in each of the four strata over the enrollment period. A, B, C, and D indicate protocol changes in the randomization procedure. These changes were made to address observed disparities in acceptance rates. On 11 April 2012, we implemented a 60%/40% split between [usual care + individual reward + collaborative reward arms] and [individual deposit + competitive deposit arms] (A). On 25 April 2012, we changed to an 80%/20% split between the same two groups (B). On 14 September 2012, we changed to a 50%/50% split between the same two groups (C). On 26 September 2012, we retained this 50%/50% split, continued the adaptive randomization for the deposit arms, but among the 50% of participants randomized to the group containing the other three arms, we fixed the allocation probabilities for the usual care (15%), individual reward (15%) and collaborative reward (70%) arms to bolster assignment to the latter (D).

References

    1. Marcus AC, Kaplan CP, Crane LA, Berek JS, Bernstein G, Gunning JE, et al. Reducing loss-to-follow-up among women with abnormal pap smears: results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care. 1998;36:397–410. doi: 10.1097/00005650-199803000-00015.
    1. Volpp KG, Loewenstein G, Troxel AB, Doshi J, Price M, Laskin M, et al. A test of financial incentives to improve warfarin adherence. BMC Health Serv Res. 2008;8:272. doi: 10.1186/1472-6963-8-272.
    1. Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G, et al. Financial incentive-based approaches for weight loss: a randomized trial. JAMA. 2008;300:2631–7. doi: 10.1001/jama.2008.804.
    1. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med. 2009;360:699–709. doi: 10.1056/NEJMsa0806819.
    1. Charness G, Gneezy U. Incentives to exercise. Econometrica. 2009;77:909–31. doi: 10.3982/ECTA7416.
    1. Jeffery RW, Gerber WM, Rosenthal BS, Lindquist RA. Monetary contracts in weight control: effectiveness of group and individual contracts of varying size. J Consult Clin Psychol. 1983;51:242–8. doi: 10.1037/0022-006X.51.2.242.
    1. Halpern SD, Asch DA, Volpp KG. Commitment contracts as a way to health. BMJ. 2012;344:522. doi: 10.1136/bmj.e522.
    1. Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials. 1988;9:312–26. doi: 10.1016/0197-2456(88)90046-3.
    1. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206–9. doi: 10.7326/0003-4819-151-3-200908040-00126.
    1. Halpern SD. Prospective preference assessment: a method to enhance the ethics and efficiency of randomized controlled trials. Control Clin Trials. 2002;23:274–88. doi: 10.1016/S0197-2456(02)00191-5.
    1. Baiocchi M, Cheng J, Small DS. Instrumental variable methods for causal inference. Stat Med. 2014;33:2297–340. doi: 10.1002/sim.6128.
    1. Brown CH, Ten Have TR, Jo B. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009;30:1–25. doi: 10.1146/annurev.publhealth.031308.100223.
    1. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103–15. doi: 10.2307/2529712.
    1. Wei LJ. An application of an urn model to the design of sequential controlled clinical trials. J Am Stat Assoc. 1978;73:559–63. doi: 10.1080/01621459.1978.10480054.
    1. Birkett NJ. Adaptive allocation in randomized controlled trials. Control Clin Trials. 1985;6:146–55. doi: 10.1016/0197-2456(85)90120-5.
    1. Zelen M. Play the winner rule and the controlled clinical trial. J Am Stat Assoc. 1969;64:131–46. doi: 10.1080/01621459.1969.10500959.
    1. Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J Am Stat Assoc. 1978;73:840–3. doi: 10.1080/01621459.1978.10480109.
    1. Hu F, Zhang Y. Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials. Ann Statist. 2004;32:268–301.
    1. Holland PW. Causal inference, path analysis, and recursive structural equations models. Sociol Methodol. 1988;18:449–84. doi: 10.2307/271055.
    1. West SG, Duan N, Pequegnat W, Gaist P, Des Jarlais DC, Holtgrave D, et al. Alternatives to the randomized controlled trial. Am J Public Health. 2008;98:1359–66. doi: 10.2105/AJPH.2007.124446.
    1. Chen YP. Biased coin design with imbalance tolerance. Comm Statist Stochastic Models. 1999;15:953–75. doi: 10.1080/15326349908807570.
    1. Asch DA, Volpp KG. On the way to health. LDI Issue Brief. 2012;17:1–4.
    1. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Stat Med. 1991;10:45–52. doi: 10.1002/sim.4780100110.
    1. Angrist AD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;91:444–55. doi: 10.1080/01621459.1996.10476902.
    1. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17–34. doi: 10.1146/annurev.publhealth.19.1.17.
    1. Angrist JD. Estimation of limited dependent variable models with dummy endogenous regressors: Simple strategies for empirical practice. J Bus Econ Stat. 2001;19:2–16. doi: 10.1198/07350010152472571.
    1. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48–55. doi: 10.1177/1740774511420743.

Source: PubMed

3
Předplatit